Hepatosplenic T-cell lymphoma, immunosuppressive agentsand biologicals: what are the risks?

Loading...
Thumbnail Image

Date

Authors

Subramaniam, Kavitha
Yeung, D.
Grimpen, F.
Joseph, J.
Fay, K.
Buckland, M.
Talaulikar, Dipti
Elijah, J.
Clarke, A. C.
Pavli, Paul

Journal Title

Journal ISSN

Volume Title

Publisher

Blackwell Science Asia

Abstract

We present three cases of the rare hepatosplenic T-cell lymphoma (HSTCL); two patients suffering from Crohn disease who developed HSTCL on azathioprine without exposure to biologicals, and a third patient who had psoriasis treated using etanercept, cyclosporine and methotrexate. The evidence for an association between HSTCL and immunosuppressive drugs and biologicals is reviewed. We argue for improved pharmacovigilance processes to help determine the benefit to risk ratios for the use of these and other new agents.

Description

Keywords

Citation

Source

Internal Medicine Journal

Book Title

Entity type

Access Statement

License Rights

Restricted until

2037-12-31